Zurn Elkay Water Solutions Corp (ZWS) Stock Price & Analysis

Zurn Elkay Water Solutions Corp (ZWS) rose 2.33% to USD 48.32 as of June 10, 2026 at 02:21 UTC, according to Nexqual real-time market data.

ZWS last closed at USD 47.22; the session ranged USD 47.58–48.73 on volume of 518,270 shares. Market capitalization is $8.10B, with a 52-week range of USD 35.06–53.76 (NYQ). Source: Nexqual, June 10, 2026 at 02:21 UTC.

Key Statistics (as of June 10, 2026 at 02:21 UTC)

PriceUSD 48.32
Change▲ 2.33% (up)
Previous CloseUSD 47.22
OpenUSD 48.07
Day RangeUSD 47.58 – 48.73
52-Week RangeUSD 35.06 – 53.76
Volume518,270 shares
Market Cap$8.10B
ExchangeNYQ

Technical Analysis (ZWS)

Nexqual's technical model rates ZWS "NEUTRAL" based on 2 bullish and 3 bearish signals across 124 daily candles, as of June 10, 2026 at 02:21 UTC.

Overall SignalNEUTRAL
RSI (14)46.68 (neutral)
vs SMA50Below (USD 48.58)
MACD-0.45 (negative)

Analyst Ratings (ZWS)

Wall Street analysts rate ZWS "Buy" based on 9 analysts, with a mean price target of USD 56.22 (range USD 52–65), per Nexqual as of June 10, 2026 at 02:21 UTC.

Consensus RatingBuy
Analyst Count9
Mean TargetUSD 56.22
High TargetUSD 65
Low TargetUSD 52
Buy / Hold / Sell4 / 6 / 0

Earnings (ZWS)

Next Earnings Date2026-04-21
EPS EstimateUSD 0.47
Revenue Estimate$483.10M

Recent Earnings History

QuarterActual vs Estimate
2026-03-31USD 0.41 vs est 0.36 ▲ beat
2025-12-31USD 0.36 vs est 0.34 ▲ beat
2025-09-30USD 0.43 vs est 0.4 ▲ beat
2025-06-30USD 0.42 vs est 0.36 ▲ beat

Source: Nexqual, June 10, 2026 at 02:21 UTC.

Financials & Fundamentals (ZWS)

Total Revenue$1.74B
Revenue Growth (YoY)+11.40%
Gross Margin+45.38%
Operating Margin+19.12%
Profit Margin+12.26%
ROE+13.33%
Debt / Equity34.37
Current Ratio3.24
Total Cash$273.50M
Total Debt$552.20M
Free Cash Flow$276.22M

Source: Nexqual, June 10, 2026 at 02:21 UTC.

Financial Health Score (ZWS)

Nexqual rates Zurn Elkay Water Solutions Corp's overall financial health "Solid" across five dimensions, as of June 10, 2026 at 02:21 UTC.

GrowthSolid — Revenue +8% YoY (annual)
ProfitabilityStrong — Gross margin 45%, operating 19%
Balance SheetStrong — $274M cash vs $552M debt
Cash FlowStrong — FCF $276M, 16% margin
EfficiencyMixed — ROE 13%, ROA 7.2%

Ownership (ZWS)

Insider Ownership+11.81%
Institutional Ownership+92.50%
Shares Outstanding166.87M
Float148.03M
Short % of Float+3.57%

Source: Nexqual, June 10, 2026 at 02:21 UTC.

Leadership (ZWS)

Zurn Elkay Water Solutions Corp is led by Todd A. Adams (age 54), CEO & Chairman, per Nexqual as of June 10, 2026 at 02:21 UTC.

CEO & ChairmanTodd A. Adams (age 54)
PresidentJeffrey A. Schoon (age 42)
Chief Operating OfficerDavid J. Pauli (age 43)
Chief Financial OfficerDaniel J. Klun (age 50)
Vice President of Marketing, Corporate Communications & SustainabilityAngela Hersil

Major Backers & Investors (ZWS)

Notable institutional backers of Zurn Elkay Water Solutions Corp include Kayne Anderson Rudnick Investment Management LLC, Bank of America Corporation, Invesco, according to Nexqual as of June 10, 2026 at 02:21 UTC.

Active Investors

InvestorStake
Kayne Anderson Rudnick Investment Management LLC6.5%
Bank of America Corporation3.37%
Invesco2.76%
Beck, Mack & Oliver LLC2.1%
Janus Henderson Group PLC1.98%
T. Rowe Price1.05%

Index Funds (Passive)

FundStake
BlackRock21.94%
Vanguard Group17.1%
State Street3.38%
Geode Capital2.18%

Source: Nexqual, June 10, 2026 at 02:21 UTC.

From Zurn Elkay Water Solutions Corp's Latest SEC 10-K Filing (filed 2026-02-09)

Key Strengths & Strategy (as disclosed to the SEC)

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

SymbolNamePriceChange
RRXRegal Rexnord CorporationUSD 213.3▲ 4.35%
HAYWHayward Holdings, Inc.USD 14.7▲ 4.48%
FTDRfrontdoor, inc.USD 65.87▲ 3.5%
ESABESAB CorporationUSD 88.48▲ 0.6%
PRVAPrivia Health Group, Inc.USD 22.17▲ 2.5%

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:21 UTC. This page is informational and not investment advice.